Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Licitra L, Tahara M, Harrington K, Olivera Hurtado de Mendoza M, Guo Y, Aksoy S, Fang M, Csőszi T, Klochikhin M, Bueno de Oliveira T, Takahashi S, Yang MH, Swiecicki PL, Even C, Fayette J, Dutcus C, Okpara CE, Shen J, Benjamin K, Gumuscu B, Haddad RI, LEAP-010 investigators

Open source

DOI: 10.1200/jco-25-00570
Published: 2026 Apr 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00570,
  title = {Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.},
  author = {Licitra L and Tahara M and Harrington K and Olivera Hurtado de Mendoza M and Guo Y and Aksoy S and Fang M and Csőszi T and Klochikhin M and Bueno de Oliveira T and Takahashi S and Yang MH and Swiecicki PL and Even C and Fayette J and Dutcus C and Okpara CE and Shen J and Benjamin K and Gumuscu B and Haddad RI and LEAP-010 investigators},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-00570},
  url = {https://doi.org/10.1200/jco-25-00570}
}

RIS

TY  - JOUR
TI  - Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.
AU  - Licitra L
AU  - Tahara M
AU  - Harrington K
AU  - Olivera Hurtado de Mendoza M
AU  - Guo Y
AU  - Aksoy S
AU  - Fang M
AU  - Csőszi T
AU  - Klochikhin M
AU  - Bueno de Oliveira T
AU  - Takahashi S
AU  - Yang MH
AU  - Swiecicki PL
AU  - Even C
AU  - Fayette J
AU  - Dutcus C
AU  - Okpara CE
AU  - Shen J
AU  - Benjamin K
AU  - Gumuscu B
AU  - Haddad RI
AU  - LEAP-010 investigators
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-00570
UR  - https://doi.org/10.1200/jco-25-00570
ER  -

APA

L, L., M, T., K, H., M, O. H. D. M., Y, G., S, A., M, F., T, C., M, K., T, B. D. O., S, T., MH, Y., PL, S., C, E., J, F., C, D., CE, O., J, S., K, B., B, G., RI, H., & investigators, L. (2026). Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-00570

Source records

pubmed · retrieved 2026-09-27T14:01:28.451Z